In this interactive session, Life Sciences CEOs will explain what their concerns are while evaluating opportunities outside their organizations and maximizing the opportunities inside their organizations. Topics will include:
- How does a CEO incorporate shareholder valuation into the due diligence process?
- How do you measure acceptable risk?
- What due diligence factors do you use in selecting a partner for a collaboration agreement?
Panelists include: George Daniloff, CEO, Carbylan BioSurgery; Dinesh V. Patel, Ph.D., President and CEO, Arête Therapeutics; Tom Moran, Of Counsel, Foley; Jay Sheppard, President and Chief Executive Officer, Relypsa, Inc.; and James A. D. Smith, President and Chief Executive Officer, Genelabs.
Related Insights
21 March 2025
IP Litigation Current
Federal Circuit Opens the Door to Additional Domestic Industry Investment: “Ordinary Importer” No Longer
In its recent decision in Lashify, Inc. v. International Trade Commission, the Federal Circuit opened the door for patent owners to include expanded categories of domestic investment to satisfy the economic prong of the domestic industry requirement under Section 337(a)(3)(B).
21 March 2025
Manufacturing Industry Advisor
Federal Court Rejects FCA’s “65%-100%” Language as Insufficient to Constitute the Necessary Quantity Term in a Requirements Contract—A Win for Suppliers
A recent federal court decision marks an important win for automotive suppliers in the ongoing debate over what constitutes a valid requirements contract under Michigan law following the Michigan Supreme Court’s decision in MSSN, Inc. v. Airboss Flexible Products Co. (2023).
27 April 2025
Events
Innovative Payment Strategies in Proton Therapy: Addressing Challenges and Driving Value
Foley partner Kinal Patel is speaking at the 2025 National Proton Conference in a panel titled “Innovative Payment Strategies in Proton Therapy: Addressing Challenges and Driving Value” on April 27.